Summary
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
History
4D Molecular Therapeutics was founded in 2014. The company is based in Emeryville, California and is focused on developing gene therapy treatments for eye diseases and the central nervous system.
Mission
Our mission is to develop and deliver transformative gene therapies that enable enhanced patient experiences and improve quality of life.
Vision
Our vision is to become the leader in developing targeted and programmable gene therapies to treat ophthalmic, central nervous system, and other diseases with unmet medical needs.
Key Team
Dr. Robert Y. Kim M.B.A., M.D. (Sr. VP & Clinical Therapeutic Area Head of Ophthalmology)
Dr. Raphael Schiffmann M.D. (Sr. VP & Therapeutic Area Head of Cardiology)
Mike Zanoni (VP of Investor Relations)
Dr. Scott P. Bizily J.D., Ph.D. (Chief Legal & HR Officer and Corp. Sec.)
Dr. Robert S. Fishman (Chief Medical Officer & Therapeutic Area Head of Pulmonology)
Mr. August J. Moretti Esq., J.D. (Chief Financial Officer)
Dr. Fred Kamal Ph.D. (Pres & COO)
Recognition and Awards
4D Molecular Therapeutics has won numerous awards and recognitions including Federation of American Societies for Experimental Biology Innovator Award, Endpoints News 2020 Deal of the Year Award, and Red Herring Top 100 North America Award.
References
United States 